Lawson Kroeker Investment Management Inc. NE Sells 18,277 Shares of Charles River Laboratories International, Inc. $CRL

Lawson Kroeker Investment Management Inc. NE decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 36.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 31,638 shares of the medical research company’s stock after selling 18,277 shares during the period. Charles River Laboratories International accounts for about 1.9% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 22nd biggest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Charles River Laboratories International were worth $6,311,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of CRL. Vanguard Group Inc. boosted its stake in Charles River Laboratories International by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after acquiring an additional 27,989 shares during the last quarter. Ariel Investments LLC raised its position in shares of Charles River Laboratories International by 28.6% during the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after acquiring an additional 314,572 shares during the last quarter. Invesco Ltd. raised its position in shares of Charles River Laboratories International by 1.0% during the 3rd quarter. Invesco Ltd. now owns 1,249,178 shares of the medical research company’s stock valued at $195,446,000 after acquiring an additional 12,035 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Charles River Laboratories International by 13.4% in the 3rd quarter. Bank of America Corp DE now owns 1,163,348 shares of the medical research company’s stock valued at $182,017,000 after purchasing an additional 137,335 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,130,905 shares of the medical research company’s stock worth $176,909,000 after purchasing an additional 120,207 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $173.71 on Friday. The firm has a market cap of $8.57 billion, a P/E ratio of -58.69, a PEG ratio of 2.11 and a beta of 1.61. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The firm’s 50 day moving average price is $174.54 and its two-hundred day moving average price is $181.07.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. During the same period last year, the business posted $2.66 earnings per share. The firm’s quarterly revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CRL shares. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research note on Thursday, February 19th. Citigroup increased their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, January 21st. JPMorgan Chase & Co. upped their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Finally, Barclays cut their price target on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, February 19th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.15.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.